Journal article
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
O Akkerman, A Aleksa, JW Alffenaar, NH Al-Marzouqi, M Arias-Guillén, E Belilovski, E Bernal, MJ Boeree, SE Borisov, J Bruchfeld, J Cadiñanos Loidi, Q Cai, JA Caminero, JJ Cebrian Gallardo, R Centis, LR Codecasa, L D'Ambrosio, M Dalcolmo, E Danila, M Dara Show all
International Journal of Infectious Diseases | ELSEVIER SCI LTD | Published : 2019
Abstract
The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries. The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs. Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated w..
View full abstractGrants
Funding Acknowledgements
The project is supported by the Global Tuberculosis Network (GTN; Committees on TB Treatment, Clinical trials and Global TB Consilium) and was part of the European Respiratory Society Latin American project in collaboration with ALAT (Asociacion Latino Americana de Torax - Latino American Thoracic Association) and SBPT (Brazilian Society of Pulmonology and Tuberculosis).